CSA Medical, Inc. — SEC Form D Filing

CSA Medical, Inc. filed an SEC Form D on July 23, 2026, reporting $2.91M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
July 23, 2026
Amount reported
$2.91M
Industry
Medical Devices
Website
https://rejuvenair.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: MARYLAND

Problem

Many Americans suffer from Chronic Bronchitis, a severe form of COPD characterized by a persistent cough, breathlessness, and wheezing. Existing treatments only offer symptomatic relief and do not target the underlying cause of the disease, leading to a significant decline in patients' quality of life.

Solution

The RejuvenAir System is a cryosurgical device that delivers liquid nitrogen to targeted areas in the lungs through a minimally invasive bronchoscopic procedure. This 'metered cryospray' destroys diseased cells while preserving the extracellular structure, allowing healthy cells to repopulate and thereby treating the underlying cause of COPD with Chronic Bronchitis.

Verdict

This cleared because it brought a novel ablation modality to an underserved, symptomatic, high-comorbidity patient population, not because it promised a transformative cure for a vast market. Investors were implicitly betting on a regulatory pathway that valued symptomatic improvement in a difficult-to-treat segment, recognizing the limited alternatives. Upside was likely capped by the niche application and the hurdle of physician adoption for a new, bronchoscopic-delivered device, rather than a broad market disruption.

Source: SEC EDGAR Form D filing